ストックスクリーナーアプリを入手
2.46
4.28%
-0.11
アフターアワーズ：
2.46
前日終値:
$2.57
開ける：
$2.57
24時間の取引高:
8.07M
Relative Volume:
0.92
時価総額：
$2.33B
収益：
$1.31M
当期純損益:
$-597.65M
株価収益率:
-2.5361
EPS:
-0.97
ネットキャッシュフロー:
$-425.62M
1週間 パフォーマンス:
-5.02%
1か月 パフォーマンス:
+5.13%
6か月 パフォーマンス:
-18.27%
1年 パフォーマンス:
-33.87%
1日の値動き範囲:
$2.41
$2.57
1週間の範囲:
$2.38
$2.65
52週間の値動き範囲:
$1.83
$7.48
Immunitybio Inc Stock (IBRX) Company Profile
IBRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.46 | 2.43B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-20 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | BTIG Research | Buy |
| 2023-05-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 開始されました | Jefferies | Buy |
Immunitybio Inc (IBRX) 最新ニュース
Does ImmunityBio Inc. show high probability of reboundJuly 2025 Institutional & Technical Confirmation Alerts - newser.com
Real time social sentiment graph for ImmunityBio Inc.Inflation Watch & Fast Entry Momentum Alerts - newser.com
ImmunityBio Inc. stock retracement – recovery analysisIndex Update & Risk Controlled Swing Trade Alerts - newser.com
What MACD and RSI say about ImmunityBio Inc.2025 Market WrapUp & Stock Timing and Entry Methods - newser.com
How ImmunityBio Inc. stock reacts to job market dataWeekly Trade Review & Capital Protection Trading Alerts - newser.com
What drives ImmunityBio Inc stock priceStock Liquidity Analysis & Free Trend Following Techniques - earlytimes.in
Short interest data insights for ImmunityBio Inc.Market Performance Report & Weekly Hot Stock Watchlists - newser.com
Why ImmunityBio Inc. (26CA) stock is a strong analyst pickTrend Reversal & High Conviction Trade Alerts - newser.com
ImmunityBio Inc Stock Analysis and ForecastDividend Cut Warnings & Outstanding Investment Portfolio - earlytimes.in
Is ImmunityBio Inc a good long term investmentTrading Volume Trends & Small Entry Trading Portfolio - Early Times
User - FinancialContent
ImmunityBio Inc. (IBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Evaluating ImmunityBio Inc. with trendline analysisTrade Signal Summary & Fast Exit and Entry Trade Guides - newser.com
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone - Investing News Network
Plancorp LLC Takes Position in ImmunityBio, Inc. $IBRX - MarketBeat
Retail Trends: Is ImmunityBio Inc part of any major indexJuly 2025 Weekly Recap & Intraday High Probability Alerts - خودرو بانک
ImmunityBio’s (IBRX) ANKTIVA Shows Survival Gains in Lung Cancer Patients - Insider Monkey
Will CTGO outperform small cap indexesQuarterly Trade Summary & Low Risk Investment Opportunities - khodrobank.com
Market Review: Should I add QULL stock to my portfolioPortfolio Profit Report & Daily Growth Stock Tips - khodrobank.com
Fed Watch: Will ImmunityBio Inc outperform its industry peersMarket Movement Recap & Long-Term Capital Growth Ideas - خودرو بانک
An Intrinsic Calculation For ImmunityBio, Inc. (NASDAQ:IBRX) Suggests It's 50% Undervalued - 富途牛牛
Earnings Update: Can ImmunityBio Inc. stock double in the next year2025 Market WrapUp & Accurate Entry/Exit Alerts - خودرو بانک
Biotech Breakouts: 3 Stocks With Massive Upside Potential - Investing.com
Biotech Breakouts: 3 Stocks With Massive Upside Potential - MarketBeat
A Look at ImmunityBio (IBRX) Valuation Following New Data on ANKTIVA’s Impact in Advanced Lung Cancer - Sahm
Insider Sell: Is ImmunityBio Inc stock a smart retirement pick2025 Biggest Moves & Real-Time Market Sentiment Reports - خودرو بانک
ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals - Stocktwits
ETF Watch: Is ImmunityBio Inc. a speculative investmentQuarterly Trade Report & Technical Confirmation Trade Alerts - خودرو بانک
Gainers Report: Is ImmunityBio Inc. forming a double bottomMarket Sentiment Summary & Technical Pattern Based Signals - خودرو بانک
Market Leaders: Will ImmunityBio Inc stock benefit from M AJuly 2025 Closing Moves & Daily Oversold Stock Bounce Ideas - خودرو بانک
Multi factor analysis applied to ImmunityBio Inc.Weekly Trade Analysis & Accurate Technical Buy Alerts - newser.com
ImmunityBio's (IBRX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Is ImmunityBio Inc. gaining market shareWeekly Trend Report & Free Weekly Chart Analysis and Trade Guides - khodrobank.com
Recap Report: Is CDTG stock technically oversoldQuarterly Growth Report & Safe Entry Zone Identification - خودرو بانک
Tech Rally: Does ImmunityBio Inc have a sustainable dividendTake Profit & Consistent Income Trade Ideas - خودرو بانک
Aug Chart Watch: Is ImmunityBio Inc a cyclical or defensive stockJuly 2025 Weekly Recap & Risk Managed Investment Strategies - khodrobank.com
ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView
RSI Check: Will ImmunityBio Inc benefit from rate cutsPortfolio Risk Report & Precise Swing Trade Entry Alerts - خودرو بانک
H.C. Wainwright Reiterates Buy Rating on ImmunityBio, Keeps PT at $8 - Yahoo Finance
Real time breakdown of ImmunityBio Inc. stock performanceWall Street Watch & Long-Term Capital Growth Ideas - newser.com
ImmunityBio (NASDAQ:IBRX) Trading 7.3% HigherHere's Why - MarketBeat
Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN
ImmunityBio's (IBRX) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Why ImmunityBio Inc. stock remains a top recommendationJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking (NASDAQ:IBRX) - Seeking Alpha
Breakthrough Findings from Phase 2 QUILT-3.055 Study in NSCLCImmunityBio, Inc. - Oncodaily
H.C. Wainwright reiterates Buy rating on ImmunityBio stock, citing promising lung cancer data - Investing.com India
H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛
ImmunityBio (IBRX): Assessing Valuation After Revealing Landmark ANKTIVA Results in Advanced Lung Cancer Study - Sahm
ImmunityBio’s Innovative Phase 2 Lymphoma Study: A Potential Game-Changer? - MSN
Sentiment Review: Is ImmunityBio Inc. a cyclical or defensive stock2025 Momentum Check & AI Forecasted Entry/Exit Points - Lancaster City Council
Immunitybio Inc (IBRX) 財務データ
収益
当期純利益
現金流量
EPS
2.36%
1.10%
大文字化:
|
ボリューム (24 時間):